Integrated Pharmaceuticals Inc - Notification that Quarterly Report will be submitted late (NT 10-Q)
2008年5月16日 - 3:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
(Check
One) [ ] Form
10-K [ ] Form
20-F [ ] Form 11-K
[X]
Form 10-Q [ ] Form 10-D
[ ] Form N-SAR [ ] Form
N-CSR
For
Period Ended:
March
31, 2008
[
] Transition Report on Form 10-K
[
] Transition Report on Form 20-F
[
] Transition Report on Form 11-K
[
] Transition Report on Form 10-Q
[
] Transition Report on Form N-SAR
For the
Transition Period Ended:
Read
Instruction (on back page) Before Preparing Form. Please Print or
Type.
Nothing
in this form shall be construed to imply that the Commission has verified any
information contained herein.
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
PART
I - REGISTRANT INFORMATION
Integrated Pharmaceuticals,
Inc.
Full Name
of Registrant
N/A
Former
Name if Applicable
310 Authority
Drive
Address
of Principal Executive Office (Street and Number)
Fitchburg, MA
01420-6047
City,
State and Zip Code
PART
II - RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
|
(a)
|
The reasons
described in reasonable detail in Part III of this form could not be
eliminated without unreasonable effort or expense;
|
|
|
|
[X]
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K,
Form 20-F, 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be
filed on or before the fifteenth calendar day following the prescribed due
date; or the subject quarterly report or transition report on Form 10-Q,
or portion thereof, will be filed on or before the fifth calendar day
following the prescribed due date; and
|
|
|
|
|
(c)
|
The accountant's
statement or other exhibit required by Rule 12b-25(c) has been attached if
applicable.
|
PART
III - NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D,
N-SAR, N-CSR, or the transition report, or portion thereof, could not be filed
within the prescribed time period.
The
Registrant is not able to file its Form 10-QSB for the period ended March 31,
2008 on the date required. The Registrant is in the process of
preparing and reviewing the financial information and compiling and
disseminating the information required to be
included
in the Form 10-QSB for the period ended March 31, 2008, as well as the
completion of the required review of the Company's financial information, none
of which could be completed by the date required without incurring undue
hardship and expense. The Registrant expects to file its Form 10-QSB
within the 5 calendar days provided by this extension.
PART
IV - OTHER INFORMATION
(1) Name
and telephone number of person to contact in regard to this
notification
Peter
Featherston
|
|
(978) 696-0020
|
|
|
(Name)
|
|
(Area
Code) (Telephone
Number
)
|
|
|
(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during
the preceding 12 months or for such shorter period that the registrant was
required to file such report(s) been filed? If answer is no, identify
report(s).
[X]
Yes [ ] No
(3) Is
it anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the
subject
report or portion thereof?
[ ]
Yes [X] No
If so,
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Integrated Pharmaceuticals,
Inc.
(Name of
Registrant as Specified in Charter)
In
accordance with section 13 or 15(d) of the Exchange Act, the registrant has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: May
15, 2008
By:
|
/s/ Peter
Featherston
|
|
|
Peter
Featherston
|
|
|
Chief
Executive Officer
|
|
|
|
|
INSTRUCTION: The
form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person signing the
form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See
18 U.S.C. 1001).
Integrated Pharmaceuticals (CE) (USOTC:INTP)
過去 株価チャート
から 5 2024 まで 6 2024
Integrated Pharmaceuticals (CE) (USOTC:INTP)
過去 株価チャート
から 6 2023 まで 6 2024